A research consortium headed by Professor Hossam Haick of the Technion-Israel Institute of Technology is developing a product that, when coupled with a smartphone, will be able to screen the user
Oxford University doctors and scientists are starting the first safety trial of an experimental preventative Ebola vaccine regimen being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen).
The Oxford Vaccine Group, part of the University of Oxford Department of Paediatrics, aims to have vaccinated all 72 healthy adult volunteers by the end of January.
The development of this prime-boost vaccine regimen has been accelerated in response to the current outbreak of Ebola virus disease in West Africa, which has claimed over 6,000 lives. An effective vaccine would be an important step in controlling the spread of disease.
Volunteers for the trial, aged 18
A collaborative effort by scientists has led to the development of an innovative strategy that can considerably improve the capabilities of medical imaging with safer procedures for the patient.
Medical imaging is a significant part of healthcare today, with imaging techniques such as magnetic resonance imaging (MRI), computed tomography (CT) scanning, and nuclear magnetic resonance (NMR) increasing greatly over the last 20 years. However, continuing problems of image resolution and quality still hinder these techniques because of the nature of living tissue. A solution is hyperpolarization, which involves injecting the patient with substances that can enhance imaging quality by following the distribution and fate of specific molecules in the body but that can be harmful or potentially toxic to the patient.
A team of scientists from Ecole Polytechnique F
Thousands of patients die each year in hospitals across North America due to medical errors that could be prevented were doctors and nurses provided with instant access to patient records via wireless technology. Cue the catch-22: the electromagnetic radiation caused by those very devices can interfere with electronic medical equipment and thus lead to serious clinical consequences for patients.
Luckily, that could soon change thanks to new research from Concordia University that helps define a clear rule of thumb for how close health-care workers with their Wi-Fi devices can be to electronic medical equipment.
In a study researchers from the Faculty of Engineering and Computer Science assessed the risk that a medical device will malfunction when radio waves that emanate from portable devices like tablet computers are present in a hospital room.
Hospitals often specify that staff members carrying wireless transmitters not approach sensitive electronic medical devices any closer than a designated minimum separation distance (MSD).
Once daily bathing with disposable cloths with the topical antimicrobial agent chlorhexidine of critically ill patients did not reduce the incidence of health care-associated infections.
Infections acquired during hospitalization (health care associated infections) are associated with increased hospital length of stay, rates of death, and increased costs. The skin of hospitalized patients is a reservoir for infectious pathogens. Subsequent invasion by skin flora is thought to be a mechanism contributing to health care-associated infections. Chlorhexidine is a broad-spectrum topical antimicrobial agent that, when used to bathe the skin, may decrease the bacterial burden, thereby reducing infections. Chlorhexidine bathing is incorporated into some expert guidelines, according to background information in the article.
Michael J. Noto, M.D., Ph.D., of Vanderbilt University, Nashville, Tenn., and colleagues conducted a study in which five adult intensive care units in Nashville performed once-daily bathing of all patients (n = 9,340) with disposable cloths impregnated with 2 percent chlorhexidine or non-antimicrobial cloths as a control. Bathing treatments were performed for a 10-week period followed by a 2-week washout period (a period allowed in order to eliminate the effect of the first intervention before starting a new intervention), during which patients were bathed with non-antimicrobial disposable cloths, before switching to the alternate bathing treatment for another 10 weeks.
A total of 55 infections occurred during the chlorhexidine bathing period (4 central line-associated bloodstream infections [CLABSIs], 21 catheter-associated urinary tract infections [CAUTIs], 17 ventilator-associated pneumonia [VAP], and 13 Clostridium difficile) and 60 infections during the control bathing periods (4 CLABSI, 32 CAUTI, 8 VAP, and 16 C difficile infections). After adjusting for various factors, no significant difference between groups in the rate of the primary outcome (composite of these infections) was detected.
Other infection-related secondary outcomes, including health care-associated bloodstream infections, blood culture contamination, and clinical cultures positive for multi-drug resistant organisms were also not improved by chlorhexidine.
Scientists at the University of York have discovered a potential new treatment for prostate cancer using low temperature plasmas (LTPs).
The study is the first time LTPs have been applied on cells grown directly from patient tissue samples. It is the result of a unique collaboration between the York Plasma Institute in the Department of Physics and the Cancer Research Unit (CRU) in York
Paramedics and emergency medical technicians (EMTs) are trained to save lives. But they sometimes enter situations where a dying patient
Two UH engineering professors have developed novel optical probes with potential applications in improving diagnosis and treatment for patients with kidney disease.
Wei-Chuan Shih, assistant professor of electrical and computer engineering, and Chandra Mohan, Hugh Roy and Lillie Cranz Cullen Endowed Professor of biomedical engineering, began collaborating just over a year ago. Shih
A new, non-invasive nuclear medicine test can be used to determine whether aromatase inhibitor treatment will be effective for specific cancer patients, according to a recent study. The research shows that a PET scan with the ligand C-11-vorozole reliably detects aromatase in all body organs
Schizophrenia, which affects 2 million to 3 million people in the U.S., causes hallucinations, delusions and disorganization. Left untreated, the disease can cause a significant loss in quality of life, including unemployment and estrangement from loved ones. But many people with schizophrenia can control the disorder and live without symptoms for several years if they consistently take prescribed antipsychotic medication, typically a daily pill.
The problem is that many people don
Tramstraat 15
5611CM Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com
PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.
